Literature DB >> 11792917

False-positive results of the NMP22 test due to hematuria.

Necmettin Atsü1, Sinan Ekici, Omer Oge O, Ali Ergen, Güslen Hasçelik, Haluk Ozen.   

Abstract

PURPOSE: The problem with available markers for bladder cancer is their low specificity and low positive predictive value due to false-positive results. False-positive results of the NMP22 nuclear matrix protein test (Matritech, Cambridge, Massachusetts) are usually observed in some clinical categories that are usually associated with hematuria and pyuria. This problem is especially serious in bladder cancer since 85% of patients present with hematuria. We investigated the effect of the degree of hematuria and pyuria on NMP22 results in an experimental model and human subjects.
MATERIALS AND METHODS: This study was performed in 202 urine samples from 30 healthy individuals (group 1), 20 with symptomatic urinary tract infection (group 2) and 32 with known bladder carcinoma (group 3). In the first group to achieve 0, 10, 100, 1,000 and 5,000 red blood cells per high power field the blood obtained from each patient was added to test tubes at 0.02, 0.2, 2 and 10 microl, respectively.
RESULTS: In the first group median urinary NMP22 in healthy individuals was 4 units per ml. (range 1.6 to 9.5). When blood was added to the urine sample, the NMP22 increase paralleled the increase in the amount of red blood cells in the sediment. When greater than 2 microl./ml. blood or 1,039.5 red blood cells per high power field (range 278 to 1,438) were added to the urine of a healthy individual, the NMP22 level reached and surpassed the level in patients with bladder carcinoma. The leukocyte count in the urine sediment also had a significant impact on urinary NMP22 in group 2. The degree of hematuria and pyuria did not significantly effect NMP22 in group 3. The sensitivity, specificity, positive and negative predictive values of NMP22 were 78.1%, 66%, 59.5% and 82.5%, respectively. Test sensitivity increased as grade and stage progressed.
CONCLUSIONS: In an experimental model pyuria and hematuria significantly affected urinary NMP22. The effect of white blood cells was more pronounced than that of red blood cells. The source of NMP22 in isolated hematuria remains to be elucidated. On the other hand, in group 3 the tumor was the main source of NMP22, and urinary erythrocytes and/or leukocytes had a negligible effect.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11792917

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  19 in total

1.  Influence of age on false positive rates of urine-based tumor markers.

Authors:  M Horstmann; T Todenhöfer; J Hennenlotter; S Aufderklamm; J Mischinger; U Kuehs; G Gakis; A Stenzl; C Schwentner
Journal:  World J Urol       Date:  2012-07-18       Impact factor: 4.226

2.  No influence of smoking status on the performance of urine markers for the detection of bladder cancer.

Authors:  Susanne Deininger; J Hennenlotter; S Rausch; K Docktor; E Neumann; I A da Costa; J Bedke; A Stenzl; T Todenhöfer
Journal:  J Cancer Res Clin Oncol       Date:  2018-04-19       Impact factor: 4.553

Review 3.  Current Concepts in the Management of Muscle Invasive Bladder Cancer.

Authors:  Suprita R Krishna; Badrinath R Konety
Journal:  Indian J Surg Oncol       Date:  2016-12-15

4.  Usefulness of the NMP22BladderChek Test for Screening and Follow-up of Bladder Cancer.

Authors:  Hwa Sub Choi; Sang Ik Lee; Dong Jun Kim; Tae Yoong Jeong
Journal:  Korean J Urol       Date:  2010-02-18

Review 5.  What are the currently available and in development molecular markers for bladder cancer? Will they prove to be useful in the future?

Authors:  Mohamed Ismat Abdulmajed; Eyüp Burak Sancak; Berkan Reşorlu; Gydhia Zuhair Al-Chalaby
Journal:  Turk J Urol       Date:  2014-10-15

Review 6.  Defining the role of NMP22 in bladder cancer surveillance.

Authors:  Carvell T Nguyen; J Stephen Jones
Journal:  World J Urol       Date:  2007-12-04       Impact factor: 4.226

7.  Point-of-Care Tests for Bladder Cancer: The Influencing Role of Hematuria.

Authors:  Joerg Hennenlotter; Severine Huber; Tilman Todenhöfer; Ursula Kuehs; David Schilling; Stefan Aufderklamm; Georgios Gakis; Christian Schwentner; Arnulf Stenzl
Journal:  Adv Urol       Date:  2011-11-22

Review 8.  Development of biomarkers of genitourinary cancer using mass spectrometry-based clinical proteomics.

Authors:  Yi-Ting Chen; Cheng-Han Tsai; Chien-Lun Chen; Jau-Song Yu; Ying-Hsu Chang
Journal:  J Food Drug Anal       Date:  2018-10-27       Impact factor: 6.157

9.  Influencing factors on the NMP-22 urine assay: an experimental model.

Authors:  Makito Miyake; Steve Goodison; Evan Gomes Giacoia; Wasia Rizwani; Shanti Ross; Charles J Rosser
Journal:  BMC Urol       Date:  2012-08-28       Impact factor: 2.264

Review 10.  Bladder cancer detection and monitoring: assessment of urine- and blood-based marker tests.

Authors:  Steve Goodison; Charles J Rosser; Virginia Urquidi
Journal:  Mol Diagn Ther       Date:  2013-04       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.